বাংলাদেশ - ইংরেজি - DGDA (Directorate General of Drug Administration)

synovia pharma plc. - gallamine triethiodide - injection - 120 mg/3 ml

কানাডা - ইংরেজি - Health Canada

alnylam netherlands b.v. - patisiran (patisiran sodium) - solution - 2mg - patisiran (patisiran sodium) 2mg - other miscellaneous therapeutic agents

কানাডা - ইংরেজি - Health Canada

alnylam netherlands b.v. - givosiran (givosiran sodium) - solution - 189mg - givosiran (givosiran sodium) 189mg - other miscellaneous therapeutic agents

কানাডা - ইংরেজি - Health Canada

alnylam netherlands b.v. - lumasiran (lumasiran sodium) - solution - 94.5mg - lumasiran (lumasiran sodium) 94.5mg

কানাডা - ইংরেজি - Health Canada

alnylam netherlands b.v. - vutrisiran (vutrisiran sodium) - solution - 25mg - vutrisiran (vutrisiran sodium) 25mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

alnylam pharmaceuticals, inc. - givosiran sodium (unii: 5xe21e41rt) (givosiran - unii:rov204583w) - givlaari is indicated for the treatment of adults with acute hepatic porphyria (ahp). givlaari is contraindicated in patients with known severe hypersensitivity to givosiran. reactions have included anaphylaxis [see warnings and precautions (5.1)]. risk summary in animal reproduction studies, subcutaneous administration of givosiran to pregnant rabbits during the period of organogenesis resulted in adverse developmental outcomes at doses that produced maternal toxicity (see data). there are no available data with givlaari use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. consider the benefits and risks of givlaari for the mother and potential adverse effects to the fetus when prescribing givlaari to a pregnant woman. the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. gene

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

alnylam pharmaceuticals, inc. - lumasiran (unii: rzt8c352o1) (lumasiran - unii:rzt8c352o1) - oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (ph1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see clinical pharmacology (12.1), clinical studies (14.1, 14.2, 14.3)] . none. risk summary there are no available data with the use of oxlumo in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. no adverse effects on pregnancy or embryo-fetal development related to oxlumo were observed in rats at 45 times and in rabbits at 90 times the maximum recommended human dose in women (see data ). the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in an emb

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

alnylam pharmaceuticals, inc. - vutrisiran (unii: gb4i2ji8ui) (vutrisiran - unii:gb4i2ji8ui) - amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. none. risk summary there are no available data on amvuttra use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. amvuttra treatment leads to a decrease in serum vitamin a levels, and vitamin a supplementation is advised for patients taking amvuttra. vitamin a is essential for normal embryofetal development; however, excessive levels of vitamin a are associated with adverse developmental effects. the effects on the fetus of a reduction in maternal serum ttr caused by amvuttra and of vitamin a supplementation are unknown [see warnings and precautions (5.1) and clinical pharmacology (12.2)] . in animal studies, subcutaneous administration of vutrisiran to pregnant rats resulted in developmental toxicity (reduced fetal body weight and embryofetal mortality) at doses associated with maternal toxicity (see data) . in the u.s. general population, the estimated

ফিলিপাইন - ইংরেজি - FDA (Food And Drug Administration)

n/a; importer: bliss pharma distribution and consultancy corp.; distributor: afree pharmaceutical distribution corp - thiamine hydrochloride (vit. b1) , pyridoxine hydrochloride (vit. b6) , cyanocoballamin (vit. b12) - solution for injection (im/iv) - 100mg/100mg/1mg per 3 ml

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alnylam australia pty ltd - givosiran sodium, quantity: 200 mg (equivalent: givosiran, qty 189 mg) - injection, solution - excipient ingredients: phosphoric acid; sodium hydroxide; water for injections - givlaari is indicated for the treatment of acute hepatic porphyria (ahp) in adults and adolescents aged 12 years and older.